Zynerba Pharmaceuticals Announces Poster Presentations at the American Academy of Neurology (AAN) 2020 Annual Meeting
March 09 2020 - 8:30AM
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in
innovative pharmaceutically-produced transdermal cannabinoid
therapies for rare and near-rare neuropsychiatric disorders, today
announced the acceptance and presentation details of three posters
at the American Academy of Neurology (AAN) 2020 Annual Meeting. The
meeting is being held in Toronto, Canada from April 25th through
May 1, 2020.
“These new data at AAN provide additional
information on the safety and observed experimental profile of
activity of Zygel™ in the exploratory Phase 2 FAB-C trial in
Fragile X syndrome and the Phase 2 BELIEVE 1 trial in developmental
and epileptic encephalopathies, and the potential of Zygel to
improve patient quality of life,” said Joseph Palumbo, MD,
FAPA, MACPsych, Chief Medical Officer of Zynerba. “On behalf of the
families and investigators participating in the Zygel clinical
development program, we are excited to share these study findings
and key learnings with the larger scientific community attending
AAN this year.”
Wednesday, April 29 from 8:00 AM to 9:00
AM.
Poster Title: "Cannabidiol Transdermal Gel in
Children and Adolescents with Developmental and Epileptic
Encephalopathies: An Open-label Clinical Trial"Abstract number:
1631Poster session: P11Poster grouping: Epilepsy/Clinical
Neurophysiology (EEG): Antiepileptic Medications/Neurostimulation
and Diet Therapies 1 (in Poster Neighborhood #4)Presentation
number: 007
Poster Title: "Quality of Life and Qualitative
Caregiver Assessments in Children and Adolescents with
Developmental and Epileptic Encephalopathies Treated with
Cannabidiol Transdermal Gel: An Open-label Clinical Trial"Abstract
number: 1664Poster session: P11Poster grouping: Epilepsy/Clinical
Neurophysiology (EEG): Antiepileptic Medications/Neurostimulation
and Diet Therapies 1 (in Poster Neighborhood #4)Presentation
number: 006
Thursday, April 30 from 12:00 PM to 1:00
PM.
Poster Title: "Cannabidiol Transdermal Gel for the
Treatment of Fragile X Syndrome: Post hoc Responder Analysis and
Pattern of Efficacy on domains of the Aberrant Behavior
Checklist-FXS (ABC-CFXS)"Abstract number: 4743Poster session:
P15Poster grouping: Child Neurology and Developmental Neurology:
Neurogenetics 3 (in Poster Neighborhood #11)Presentation number:
002
About Zynerba Pharmaceuticals,
Inc.
Zynerba Pharmaceuticals is the leader in
pharmaceutically-produced transdermal cannabinoid therapies for
rare and near-rare neuropsychiatric disorders. We are committed to
improving the lives of patients and their families living with
severe, chronic health conditions including Fragile X syndrome,
autism spectrum disorder, 22q11.2 deletion syndrome, and a
heterogeneous group of rare and ultra-rare epilepsies known as
developmental and epileptic encephalopathies. Learn more at
www.zynerba.com and follow us on Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. We may, in some cases, use terms such as
“predicts,” “believes,” “potential,” “proposed,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual
events or results to differ materially from the Company’s current
expectations. These and other risks are described in the Company’s
periodic reports, including the annual report on Form 10-K,
quarterly reports on Form 10-Q and current reports on Form 8-K,
filed with or furnished to the Securities and Exchange Commission
and available at www.sec.gov. Any forward-looking statements
that the Company makes in this press release speak only as of the
date of this press release. The Company assumes no obligation to
update forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Zynerba ContactWill Roberts, VP
Investor Relations and Corporate
Communications484.581.7489robertsw@zynerba.com
Media contactMolly DevlinEvoke
KYNE215.928.2199Molly.Devlin@evokegroup.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Apr 2023 to Apr 2024